4. High Potency
Least sedating
Have no anticholinergic symptoms (dry
mouth, constipation, hot, dry skin, tachycardia, delirium in
elderly)
High tendency for EPS
Low Potency
Most sedating
Have more anticholinergic symptoms
Lower tendency for EPS
Mid Potency
Well tolerated
6. Tend not to induce EPS
Weight gain, induce onset DM (exp clozapine,
olanzapine)
Other SE, drooling, sedation, amenorrhea
Clozapine may cause agranulocytosis
WBC/ANC baseline
qWk 6 months, q2wk 6 months, q4wk > 1 year
Continue for qwk 1 month after d/c
7. EPS
Begin several hours to weeks of start treatment
Include acute dystonia (muscle spasm, stiffness), akinesia
(parkinsonian-like, decreased movements), akathisia
(restlessness, increased movements), tardive dyskinesia
(facial, distal extremities involuntary movements)
NMS
Hyperpyrexia, muscle rigidity, agitation, increased
WBC/CK/myoglobinuria
Tx= supportive, dantrolene (muscle relaxant, binds
ryanodine rec, dec Ca2+), bromocriptine (dopamine
agonist)
8. Braunwald, E., et al. (2002). Harrison’s manual of medicine.
International Edition: McGraw Hill.
Bhushan, V., Le, T. (2011). First Aid for the USMLE Step 1
2011: A Student to student guide. McGraw Hill.
Jann MW, Grimsley SR, Gray EC, Chang WH.
Pharmacokinetics and pharmacodynamics of clozapine. Clin
Pharmacokinet 1993; 24:161.
Notes de l'éditeur
Agran- wbc count below 2000cells/mm3 blood (<5% of normal)